Current Report Filing (8-k)
March 06 2017 - 9:16AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported):
|
March
4, 2017
|
Marina
Biotech, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-13789
|
|
11-2658569
|
(State
or other jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
17870
Castleton Street, Suite 250
City
of Industry, CA
|
|
91748
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
Registrant’s
telephone number, including area code:
|
626-964-5788
|
N/A
Former
name or former address, if changed since last report
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
8.01 Other Events.
On
March 4 and March 5, 2017, Dr. Vuong Trieu, the Chairman of the Board of Directors of Marina Biotech, Inc., presented a poster
on the clinical development of Celecoxib-Lisinopril FDC (IT-102) and Celecoxib-Olmesartan FDC (IT-103) against combined arthritis
/ hypertension at the 7
th
International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia
and Diabetes Mellitus in Cannes, France. A copy of the presentation is attached as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Presentation
of Marina Biotech, Inc. at the 7
th
International Conference on Fixed Combination in the Treatment of Hypertension,
Dyslipidemia and Diabetes Mellitus.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
Marina Biotech, Inc.
|
|
|
|
March
6, 2017
|
By:
|
/s/
Joseph W. Ramelli
|
|
Name:
|
Joseph
W. Ramelli
|
|
Title:
|
Chief
Executive Officer
|
EXHIBIT
INDEX
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Presentation
of Marina Biotech, Inc. at the 7
th
International Conference on Fixed Combination in the Treatment of Hypertension,
Dyslipidemia and Diabetes Mellitus.
|